Literature DB >> 22525819

HE4 is an independent prognostic marker in endometrial cancer patients.

Irene Mutz-Dehbalaie1, Daniel Egle, Siegfried Fessler, Michael Hubalek, Heidi Fiegl, Christian Marth, Andreas Widschwendter.   

Abstract

OBJECTIVE: To evaluate the prognostic value of pretherapeutic serum HE4 in endometrial cancer in comparison to CA125.
METHODS: HE4 and CA125 serum levels were analyzed by means of chemiluminescent microparticle immunoassays in 183 patients with endometrial cancer treated at the Department of Obstetrics and Gynecology, Innsbruck Medical University, between 1999 and 2009. The Kaplan-Meier method and Cox's proportional hazards analysis were performed to determine the prognostic significance of HE4, CA125 and the combination of both markers.
RESULTS: In univariate analysis both markers, HE4 and CA125, were of prognostic value for overall survival (p<0.001 and p=0.028) and disease-free survival (p=0.015 and p=0.045). In multivariate analysis HE4 was seen to have independent prognostic value in overall survival (HR 2.407, p=0.017) in contrast to CA125. The combination of both markers showed a higher hazard ratio (HR 4.04, p=0.023) for overall survival in comparison to HE4 alone. In the subgroup endometrioid histological type (n=132) only HE4 was of prognostic value for overall survival in univariate (p=0.001) and multivariate analysis (p=0.023).
CONCLUSIONS: Pretherapeutic serum HE4 levels alone and in combination with CA125 are an independent prognostic marker in endometrial cancer patients.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22525819     DOI: 10.1016/j.ygyno.2012.04.022

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  32 in total

1.  The role of HE4 in endometrial cancer recurrence: how to choose the optimal follow-up program.

Authors:  Roberto Angioli; Stella Capriglione; Giuseppe Scaletta; Alessia Aloisi; Andrea Miranda; Carlo De Cicco Nardone; Corrado Terranova; Francesco Plotti
Journal:  Tumour Biol       Date:  2015-11-03

2.  Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer.

Authors:  A Stiekema; Car Lok; C M Korse; W J van Driel; V van der Noort; G G Kenter; K K Van de Vijver
Journal:  Virchows Arch       Date:  2017-04-11       Impact factor: 4.064

3.  Endometrial and Ovarian Cancer with MR Imaging Importance of Serum HE4 and CA 125 Levels in the Extent of Disease at Evaluation.

Authors:  Emsal Pınar Topdağı Yılmaz; Yakup Kumtepe
Journal:  Eurasian J Med       Date:  2016-10

Review 4.  Current status of molecular biomarkers in endometrial cancer.

Authors:  H M J Werner; H B Salvesen
Journal:  Curr Oncol Rep       Date:  2014-09       Impact factor: 5.075

Review 5.  Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature.

Authors:  Stella Capriglione; Daniela Luvero; Francesco Plotti; Corrado Terranova; Roberto Montera; Giuseppe Scaletta; Teresa Schirò; Gianmarco Rossini; Pierluigi Benedetti Panici; Roberto Angioli
Journal:  Med Oncol       Date:  2017-08-20       Impact factor: 3.064

6.  The clinical significance of DJ-1 and HE4 in patients with endometrial cancer.

Authors:  Marco Benati; Martina Montagnana; Elisa Danese; Elisa Paviati; Silvia Giudici; Orazio Ruzzenente; Massimo Franchi; Giuseppe Lippi
Journal:  J Clin Lab Anal       Date:  2017-04-04       Impact factor: 2.352

7.  Validation of REM score to predict endometrial cancer in patients with ultrasound endometrial abnormalities: results of a new independent dataset.

Authors:  Francesco Plotti; Stella Capriglione; Corrado Terranova; Roberto Montera; Giuseppe Scaletta; Salvatore Lopez; Daniela Luvero; Antonelli Gianina; Alessia Aloisi; Pierluigi Benedetti Panici; Roberto Angioli
Journal:  Med Oncol       Date:  2017-04-07       Impact factor: 3.064

Review 8.  A critical review on HE4 performance in endometrial cancer: where are we now?

Authors:  Roberto Angioli; Andrea Miranda; Alessia Aloisi; Roberto Montera; Stella Capriglione; Carlo De Cicco Nardone; Corrado Terranova; Francesco Plotti
Journal:  Tumour Biol       Date:  2013-09-26

9.  Diagnostic Performance of Serum Human Epididymis Protein 4 in Endometrial Carcinoma: A Pilot Study.

Authors:  Rupali Dewan; Abhinav Dewan; Swati Hare; Mausumi Bhardwaj; Krati Mehrotra
Journal:  J Clin Diagn Res       Date:  2017-07-01

10.  The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients.

Authors:  Beyhan Omer; Sema Genc; Ozguc Takmaz; Ahmet Dirican; Zeynep Kusku-Kiraz; Sinan Berkman; Figen Gurdol
Journal:  Tumour Biol       Date:  2013-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.